{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,8]],"date-time":"2026-11-08T03:24:53Z","timestamp":1794108293343,"version":"4.8.0"},"reference-count":176,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,18]],"date-time":"2023-10-18T00:00:00Z","timestamp":1697587200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007219","name":"Natural Science Foundation of Shanghai Municipality","doi-asserted-by":"publisher","award":["23ZR1463300"],"award-info":[{"award-number":["23ZR1463300"]}],"id":[{"id":"10.13039\/100007219","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81703010"],"award-info":[{"award-number":["81703010"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81872428"],"award-info":[{"award-number":["81872428"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82172098"],"award-info":[{"award-number":["82172098"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82202344"],"award-info":[{"award-number":["82202344"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Acta Pharmaceutica Sinica B"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1016\/j.apsb.2023.10.012","type":"journal-article","created":{"date-parts":[[2023,10,20]],"date-time":"2023-10-20T11:50:10Z","timestamp":1697802610000},"page":"579-601","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":36,"title":["Lipid nanovehicles overcome barriers to systemic RNA delivery: Lipid components, fabrication methods, and rational design"],"prefix":"10.1016","volume":"14","author":[{"given":"Jing","family":"Yan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangfeng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiacan","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2711-2240","authenticated-orcid":false,"given":"Yan","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Can","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.apsb.2023.10.012_bib1","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1007\/s11883-021-00936-1","article-title":"The role of RNA-targeted therapeutics to reduce ASCVD risk: what have we learned recently?.","volume":"23","author":"Miname","year":"2021","journal-title":"Curr Atherosclerosis Rep"},{"key":"10.1016\/j.apsb.2023.10.012_bib2","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1038\/nature02870","article-title":"Unlocking the potential of the human genome with RNA interference","volume":"431","author":"Hannon","year":"2004","journal-title":"Nature"},{"key":"10.1016\/j.apsb.2023.10.012_bib3","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/s41573-020-0075-7","article-title":"Advances in oligonucleotide drug delivery","volume":"19","author":"Roberts","year":"2020","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.apsb.2023.10.012_bib4","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/nbt.3802","article-title":"Overcoming cellular barriers for RNA therapeutics","volume":"35","author":"Dowdy","year":"2017","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.apsb.2023.10.012_bib5","doi-asserted-by":"crossref","first-page":"3754","DOI":"10.1021\/acsnano.8b07858","article-title":"Lipid-based DNA therapeutics: hallmarks of non-viral gene delivery","volume":"13","author":"Buck","year":"2019","journal-title":"ACS Nano"},{"key":"10.1016\/j.apsb.2023.10.012_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.compositesb.2022.110288","article-title":"Optimizing the modification density of acid oligopeptides to enhance the bone-targeting activity of liposomes","volume":"247","author":"Tao","year":"2022","journal-title":"Compos B Eng"},{"key":"10.1016\/j.apsb.2023.10.012_bib7","doi-asserted-by":"crossref","DOI":"10.1002\/adfm.202100605","article-title":"Enzyme-activated prodrug-based smart liposomes specifically enhance tumor hemoperfusion with efficient drug delivery to pancreatic cancer cells and stellate cells","volume":"31","author":"Duan","year":"2021","journal-title":"Adv Funct Mater"},{"key":"10.1016\/j.apsb.2023.10.012_bib8","doi-asserted-by":"crossref","DOI":"10.1002\/advs.201902746","article-title":"MT1-MMP-activated liposomes to improve tumor blood perfusion and drug delivery for enhanced pancreatic cancer therapy","volume":"7","author":"Wei","year":"2020","journal-title":"Adv Sci"},{"key":"10.1016\/j.apsb.2023.10.012_bib9","doi-asserted-by":"crossref","first-page":"25138","DOI":"10.1021\/acsami.7b07132","article-title":"Thermosensitive liposomal codelivery of HSA-paclitaxel and HSA-ellagic acid complexes for enhanced drug perfusion and efficacy against pancreatic cancer","volume":"9","author":"Wei","year":"2017","journal-title":"ACS Appl Mater Interfaces"},{"key":"10.1016\/j.apsb.2023.10.012_bib10","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/0014-5793(78)80582-1","article-title":"Entrapment of ribonucleic acids in liposomes","volume":"86","author":"Dimitriadis","year":"1978","journal-title":"FEBS Lett"},{"key":"10.1016\/j.apsb.2023.10.012_bib11","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/S0005-2736(00)00343-6","article-title":"Efficient encapsulation of antisense oligonucleotides in lipid vesicles using ionizable aminolipids: formation of novel small multilamellar vesicle structures","volume":"1510","author":"Semple","year":"2001","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.apsb.2023.10.012_bib12","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.addr.2020.06.002","article-title":"Lipid nanoparticles for nucleic acid delivery: current perspectives","volume":"154\u2013155","author":"Samaridou","year":"2020","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.apsb.2023.10.012_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.nantod.2021.101142","article-title":"Role of nanotechnology behind the success of mRNA vaccines for COVID-19","volume":"38","author":"Khurana","year":"2021","journal-title":"Nano Today"},{"key":"10.1016\/j.apsb.2023.10.012_bib14","first-page":"1","article-title":"Delivery systems for siRNA drug development in cancer therapy","volume":"10","author":"Xu","year":"2015","journal-title":"Asian J Pharm Sci"},{"key":"10.1016\/j.apsb.2023.10.012_bib15","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/j.ymthe.2019.02.012","article-title":"Delivering the messenger: advances in technologies for therapeutic mRNA delivery","volume":"27","author":"Kowalski","year":"2019","journal-title":"Mol Ther"},{"key":"10.1016\/j.apsb.2023.10.012_bib16","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/j.apsb.2022.10.004","article-title":"Lipid nanomaterials-based RNA therapy and cancer treatment","volume":"13","author":"Zhang","year":"2023","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.apsb.2023.10.012_bib17","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1016\/j.apsb.2023.03.001","article-title":"MRNA delivery in cancer immunotherapy","volume":"13","author":"Zhong","year":"2023","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.apsb.2023.10.012_bib18","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1016\/j.apsb.2020.10.005","article-title":"Small interfering RNA for cancer treatment: overcoming hurdles in delivery","volume":"10","author":"Charbe","year":"2020","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.apsb.2023.10.012_bib19","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1016\/j.apsb.2022.07.010","article-title":"Progress in non-viral localized delivery of siRNA therapeutics for pulmonary diseases","volume":"13","author":"Gao","year":"2023","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.apsb.2023.10.012_bib20","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.apsb.2021.08.009","article-title":"Pulmonary delivery of siRNA against acute lung injury\/acute respiratory distress syndrome","volume":"12","author":"Zoulikha","year":"2022","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.apsb.2023.10.012_bib21","doi-asserted-by":"crossref","first-page":"2624","DOI":"10.1016\/j.apsb.2022.04.013","article-title":"Tailoring combinatorial lipid nanoparticles for intracellular delivery of nucleic acids, proteins, and drugs","volume":"12","author":"Li","year":"2022","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.apsb.2023.10.012_bib22","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/j.addr.2009.03.004","article-title":"Lentiviral delivery of short hairpin RNAs","volume":"61","author":"Manjunath","year":"2009","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.apsb.2023.10.012_bib23","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s40035-017-0101-9","article-title":"RNAi mechanisms in Huntington\u2019 s disease therapy: siRNA versus shRNA","volume":"6","author":"Aguiar","year":"2017","journal-title":"Transl Neurodegener"},{"key":"10.1016\/j.apsb.2023.10.012_bib24","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.biotechadv.2019.04.012","article-title":"RNAi therapeutic and its innovative biotechnological evolution","volume":"37","author":"Weng","year":"2019","journal-title":"Biotechnol Adv"},{"key":"10.1016\/j.apsb.2023.10.012_bib25","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/nature21025","article-title":"An argonaute phosphorylation cycle promotes microRNA-mediated silencing","volume":"542","author":"Golden","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.apsb.2023.10.012_bib26","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1517\/14712598.8.1.59","article-title":"MicroRNAs as targets for antisense-based therapeutics","volume":"8","author":"Stenvang","year":"2008","journal-title":"Expet Opin Biol Ther"},{"key":"10.1016\/j.apsb.2023.10.012_bib27","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.3390\/pharmaceutics13122015","article-title":"Antisense oligonucleotide-based therapy of viral infections","volume":"13","author":"Tarn","year":"2021","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.apsb.2023.10.012_bib28","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1016\/j.ymthe.2017.06.002","article-title":"RNase H1-dependent antisense oligonucleotides are robustly active in directing RNA cleavage in both the cytoplasm and the nucleus","volume":"25","author":"Liang","year":"2017","journal-title":"Mol Ther"},{"key":"10.1016\/j.apsb.2023.10.012_bib29","doi-asserted-by":"crossref","first-page":"3351","DOI":"10.1093\/nar\/gkw065","article-title":"RNA cleavage products generated by antisense oligonucleotides and siRNAs are processed by the RNA surveillance machinery","volume":"44","author":"Lima","year":"2016","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.apsb.2023.10.012_bib30","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1038\/cr.2016.22","article-title":"SaRNA-guided Ago2 targets the RITA complex to promoters to stimulate transcription","volume":"26","author":"Portnoy","year":"2016","journal-title":"Cell Res"},{"key":"10.1016\/j.apsb.2023.10.012_bib31","doi-asserted-by":"crossref","first-page":"151","DOI":"10.4155\/tde-2018-0061","article-title":"Developing small activating RNA as a therapeutic: current challenges and promises","volume":"10","author":"Kwok","year":"2019","journal-title":"Ther Deliv"},{"key":"10.1016\/j.apsb.2023.10.012_bib32","doi-asserted-by":"crossref","first-page":"5069","DOI":"10.1158\/0008-5472.CAN-12-1871","article-title":"Intravesical delivery of small activating RNA formulated into lipid nanoparticles inhibits orthotopic bladder tumor growth","volume":"72","author":"Kang","year":"2012","journal-title":"Cancer Res"},{"key":"10.1016\/j.apsb.2023.10.012_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2020.109997","article-title":"RNA-based pharmacotherapy for tumors: from bench to clinic and back","volume":"125","author":"Liang","year":"2020","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.apsb.2023.10.012_bib34","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1007\/s000180050207","article-title":"Human extracellular ribonucleases: multiplicity, molecular diversity and catalytic properties of the major RNase types","volume":"54","author":"Sorrentino","year":"1998","journal-title":"Cell Mol Life Sci"},{"key":"10.1016\/j.apsb.2023.10.012_bib35","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1124\/dmd.106.009555","article-title":"Intravenously administered short interfering RNA accumulates in the kidney and selectively suppresses gene function in renal proximal tubules","volume":"34","author":"Van de Water","year":"2006","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.apsb.2023.10.012_bib36","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1172\/JCI22562","article-title":"Nephrin strands contribute to a porous slit diaphragm scaffold as revealed by electron tomography","volume":"114","author":"Wartiovaara","year":"2004","journal-title":"J Clin Invest"},{"key":"10.1016\/j.apsb.2023.10.012_bib37","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1038\/nri2448","article-title":"Exploring the full spectrum of macrophage activation","volume":"8","author":"Mosser","year":"2008","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.apsb.2023.10.012_bib38","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1042\/BJ20080474","article-title":"Focusing on clathrin-mediated endocytosis","volume":"412","author":"Rappoport","year":"2008","journal-title":"Biochem J"},{"key":"10.1016\/j.apsb.2023.10.012_bib39","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1002\/smll.201100001","article-title":"Cellular uptake, intracellular trafficking, and cytotoxicity of nanomaterials","volume":"7","author":"Zhao","year":"2011","journal-title":"Small"},{"key":"10.1016\/j.apsb.2023.10.012_bib40","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1242\/jcs.066399","article-title":"Breaking down the barriers: siRNA delivery and endosome escape","volume":"123","author":"Dominska","year":"2010","journal-title":"J Cell Sci"},{"key":"10.1016\/j.apsb.2023.10.012_bib41","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.jconrel.2010.11.004","article-title":"Endosomal escape pathways for delivery of biologicals","volume":"151","author":"Varkouhi","year":"2011","journal-title":"J Control Release"},{"key":"10.1016\/j.apsb.2023.10.012_bib42","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/S0005-2736(97)00126-0","article-title":"Toxicity and immunomodulatory activity of liposomal vectors formulated with cationic lipids toward immune effector cells","volume":"1329","author":"Filion","year":"1997","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.apsb.2023.10.012_bib43","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1007\/s13346-013-0161-z","article-title":"Lipid nanoparticle delivery systems for siRNA-based therapeutics","volume":"4","author":"Wan","year":"2014","journal-title":"Drug Deliv Transl Res"},{"key":"10.1016\/j.apsb.2023.10.012_bib44","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1023\/A:1018932714745","article-title":"Comparison of cell proliferation and toxicity assays using two cationic liposomes","volume":"11","author":"Lappalainen","year":"1994","journal-title":"Pharm Res (N Y)"},{"key":"10.1016\/j.apsb.2023.10.012_bib45","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1021\/cr800409e","article-title":"Nonviral vectors for gene delivery","volume":"109","author":"Mintzer","year":"2009","journal-title":"Chem Rev"},{"key":"10.1016\/j.apsb.2023.10.012_bib46","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1023\/A:1007504613351","article-title":"Oxygen radical-mediated pulmonary toxicity induced by some cationic liposomes","volume":"17","author":"Dokka","year":"2000","journal-title":"Pharm Res (N Y)"},{"key":"10.1016\/j.apsb.2023.10.012_bib47","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1006\/bbrc.1994.2372","article-title":"A novel cationic amphiphile for transfection of mammalian cells","volume":"203","author":"Ruysschaert","year":"1994","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.apsb.2023.10.012_bib48","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1038\/sj.gt.3302777","article-title":"A novel sirna-lipoplex technology for RNA interference in the mouse vascular endothelium","volume":"13","author":"Santel","year":"2006","journal-title":"Gene Ther"},{"key":"10.1016\/j.apsb.2023.10.012_bib49","doi-asserted-by":"crossref","first-page":"5469","DOI":"10.1158\/1078-0432.CCR-10-1994","article-title":"Atu027 prevents pulmonary metastasis in experimental and spontaneous mouse metastasis models","volume":"16","author":"Santel","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.apsb.2023.10.012_bib50","doi-asserted-by":"crossref","first-page":"9788","DOI":"10.1158\/0008-5472.CAN-08-2428","article-title":"Atu027, a liposomal small interfering RNA formulation targeting protein kinase N3, inhibits cancer progression","volume":"68","author":"Aleku","year":"2008","journal-title":"Cancer Res"},{"key":"10.1016\/j.apsb.2023.10.012_bib51","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1200\/jco.2016.34.4_suppl.385","article-title":"A phase Ib\/IIa study of combination therapy with gemcitabine and Atu027 in patients with locally advanced or metastatic pancreatic adenocarcinoma","volume":"34","author":"Schultheis","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.apsb.2023.10.012_bib52","doi-asserted-by":"crossref","first-page":"4176","DOI":"10.1021\/jm000466s","article-title":"Design, synthesis, and transfection biology of novel cationic glycolipids for use in liposomal gene delivery","volume":"44","author":"Banerjee","year":"2001","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2023.10.012_bib53","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1021\/mp800136v","article-title":"Novel cationic lipid that delivers siRNA and enhances therapeutic effect in lung cancer cells","volume":"6","author":"Chen","year":"2009","journal-title":"Mol Pharm"},{"key":"10.1016\/j.apsb.2023.10.012_bib54","doi-asserted-by":"crossref","first-page":"3105","DOI":"10.1016\/j.bmc.2013.03.048","article-title":"Novel imidazole-functionalized cyclen cationic lipids: synthesis and application as non-viral gene vectors","volume":"21","author":"Liu","year":"2013","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.apsb.2023.10.012_bib55","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1038\/sj.gt.3301506","article-title":"On the mechanism whereby cationic lipids promote intracellular delivery of polynucleic acids","volume":"8","author":"Hafez","year":"2001","journal-title":"Gene Ther"},{"key":"10.1016\/j.apsb.2023.10.012_bib56","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.jconrel.2005.06.014","article-title":"Cationic lipid saturation influences intracellular delivery of encapsulated nucleic acids","volume":"107","author":"Heyes","year":"2005","journal-title":"J Control Release"},{"key":"10.1016\/j.apsb.2023.10.012_bib57","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1038\/nature04688","article-title":"RNAi-mediated gene silencing in non-human primates","volume":"441","author":"Zimmermann","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.apsb.2023.10.012_bib58","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1038\/nbt.1602","article-title":"Rational design of cationic lipids for siRNA delivery","volume":"28","author":"Semple","year":"2010","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.apsb.2023.10.012_bib59","doi-asserted-by":"crossref","first-page":"8529","DOI":"10.1002\/anie.201203263","article-title":"Maximizing the potency of siRNA lipid nanoparticles for hepatic gene silencing in\u00a0vivo","volume":"51","author":"Jayaraman","year":"2012","journal-title":"Angew Chem Int Ed Engl"},{"key":"10.1016\/j.apsb.2023.10.012_bib60","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1038\/s41565-019-0591-y","article-title":"The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs","volume":"14","author":"Akinc","year":"2019","journal-title":"Nat Nanotechnol"},{"key":"10.1016\/j.apsb.2023.10.012_bib61","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1016\/j.ymthe.2018.03.010","article-title":"A novel amino lipid series for mRNA delivery: improved endosomal escape and sustained pharmacology and safety in non-human primates","volume":"26","author":"Sabnis","year":"2018","journal-title":"Mol Ther"},{"key":"10.1016\/j.apsb.2023.10.012_bib62","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1073\/pnas.0910603106","article-title":"Lipid-like materials for low-dose, in\u00a0vivo gene silencing","volume":"107","author":"Love","year":"2010","journal-title":"Proc Natl Acad Sci U\u00a0S\u00a0A"},{"key":"10.1016\/j.apsb.2023.10.012_bib63","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nbt1402","article-title":"A combinatorial library of lipid-like materials for delivery of RNAi therapeutics","volume":"26","author":"Akinc","year":"2008","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.apsb.2023.10.012_bib64","doi-asserted-by":"crossref","first-page":"3112","DOI":"10.1002\/adfm.200900519","article-title":"Lipid-like nanoparticles for small interfering RNA delivery to endothelial cells","volume":"19","author":"Cho","year":"2009","journal-title":"Adv Funct Mater"},{"key":"10.1016\/j.apsb.2023.10.012_bib65","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.addr.2020.06.026","article-title":"Lipid nanoparticle technology for therapeutic gene regulation in the liver","volume":"159","author":"Witzigmann","year":"2020","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.apsb.2023.10.012_bib66","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1081\/LPR-64971","article-title":"Liposome opsonization","volume":"15","author":"Yan","year":"2005","journal-title":"J Liposome Res"},{"key":"10.1016\/j.apsb.2023.10.012_bib67","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1016\/S0006-3495(00)76720-8","article-title":"The phase behavior of cationic lipid-DNA complexes","volume":"78","author":"May","year":"2000","journal-title":"Biophys J"},{"key":"10.1016\/j.apsb.2023.10.012_bib68","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.jconrel.2005.08.012","article-title":"The role of dioleoylphosphatidylethanolamine (DOPE) in targeted gene delivery with mannosylated cationic liposomes via intravenous route","volume":"108","author":"Hattori","year":"2005","journal-title":"J Control Release"},{"key":"10.1016\/j.apsb.2023.10.012_bib69","doi-asserted-by":"crossref","first-page":"12181","DOI":"10.1021\/acs.chemrev.1c00244","article-title":"Lipids and lipid derivatives for RNA delivery","volume":"121","author":"Zhang","year":"2021","journal-title":"Chem Rev"},{"key":"10.1016\/j.apsb.2023.10.012_bib70","doi-asserted-by":"crossref","first-page":"21733","DOI":"10.1039\/C9NR09347H","article-title":"On the role of helper lipids in lipid nanoparticle formulations of siRNA","volume":"11","author":"Kulkarni","year":"2019","journal-title":"Nanoscale"},{"key":"10.1016\/j.apsb.2023.10.012_bib71","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0939-6411(01)00165-5","article-title":"Effects of erythrocytes and serum proteins on lung accumulation of lipoplexes containing cholesterol or DOPE as a helper lipid in the single-pass rat lung perfusion system","volume":"52","author":"Sakurai","year":"2001","journal-title":"Eur J Pharm Biopharm"},{"key":"10.1016\/j.apsb.2023.10.012_bib72","doi-asserted-by":"crossref","first-page":"2564","DOI":"10.3390\/molecules23102564","article-title":"Systematic screening of commonly used commercial transfection reagents towards efficient transfection of Single-Stranded oligonucleotides","volume":"23","author":"Wang","year":"2018","journal-title":"Molecules"},{"key":"10.1016\/j.apsb.2023.10.012_bib73","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/j.ymthe.2004.08.010","article-title":"Cellular uptake of arginine-rich peptides: roles for macropinocytosis and actin rearrangement","volume":"10","author":"Nakase","year":"2004","journal-title":"Mol Ther"},{"key":"10.1016\/j.apsb.2023.10.012_bib74","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s13073-017-0450-0","article-title":"Advances in the delivery of RNA therapeutics: from concept to clinical reality","volume":"9","author":"Kaczmarek","year":"2017","journal-title":"Genome Med"},{"key":"10.1016\/j.apsb.2023.10.012_bib75","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1042\/bj1860591","article-title":"Effect of the cholesterol content of small unilamellar liposomes on their stability in\u00a0vivo and in\u00a0vitro","volume":"186","author":"Kirby","year":"1980","journal-title":"Biochem J"},{"key":"10.1016\/j.apsb.2023.10.012_bib76","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1016\/j.bbamem.2012.05.017","article-title":"Transfection efficiency boost of cholesterol-containing lipoplexes","volume":"1818","author":"Pozzi","year":"2012","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.apsb.2023.10.012_bib77","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1098\/rsif.2011.0356","article-title":"The effect of neutral helper lipids on the structure of cationic lipid monolayers","volume":"9","author":"Dabkowska","year":"2012","journal-title":"J R Soc Interface"},{"key":"10.1016\/j.apsb.2023.10.012_bib78","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1021\/bi950414i","article-title":"Influence of cholesterol on the association of plasma proteins with liposomes","volume":"35","author":"Semple","year":"1996","journal-title":"Biochemistry-Us"},{"key":"10.1016\/j.apsb.2023.10.012_bib79","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1021\/ar300048p","article-title":"Lipid-based nanoparticles for siRNA delivery in cancer therapy: paradigms and challenges","volume":"45","author":"Gomes-Da-Silva","year":"2012","journal-title":"Acc Chem Res"},{"key":"10.1016\/j.apsb.2023.10.012_bib80","doi-asserted-by":"crossref","first-page":"e37","DOI":"10.1038\/mtna.2012.28","article-title":"Microfluidic synthesis of highly potent limit-size lipid nanoparticles for in\u00a0vivo delivery of siRNA","volume":"1","author":"Belliveau","year":"2012","journal-title":"Mol Ther Nucleic Acids"},{"key":"10.1016\/j.apsb.2023.10.012_bib81","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.jconrel.2007.11.002","article-title":"Efficient gene silencing in metastatic tumor by siRNA formulated in surface-modified nanoparticles","volume":"126","author":"Li","year":"2008","journal-title":"J Control Release"},{"key":"10.1016\/j.apsb.2023.10.012_bib82","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.jhep.2008.10.029","article-title":"Targeted delivery of siRNA against hepatitis C virus by apolipoprotein A-I-bound cationic liposomes","volume":"50","author":"Kim","year":"2009","journal-title":"J Hepatol"},{"key":"10.1016\/j.apsb.2023.10.012_bib83","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.jconrel.2009.04.006","article-title":"Effect of siRNA in PEG-coated siRNA-lipoplex on anti-PEG IgM production","volume":"137","author":"Tagami","year":"2009","journal-title":"J Control Release"},{"key":"10.1016\/j.apsb.2023.10.012_bib84","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1021\/mp800157x","article-title":"Controlling HBV replication in\u00a0vivo by intravenous administration of triggered PEGylated siRNA-nanoparticles","volume":"6","author":"Carmona","year":"2009","journal-title":"Mol Pharm"},{"key":"10.1016\/j.apsb.2023.10.012_bib85","doi-asserted-by":"crossref","first-page":"4886","DOI":"10.1021\/la803973p","article-title":"Elucidating the encapsulation of short interfering RNA in PEGylated cationic liposomes","volume":"25","author":"Buyens","year":"2009","journal-title":"Langmuir"},{"key":"10.1016\/j.apsb.2023.10.012_bib86","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1021\/mp800134q","article-title":"Nonviral methods for siRNA delivery","volume":"6","author":"Gao","year":"2009","journal-title":"Mol Pharm"},{"key":"10.1016\/j.apsb.2023.10.012_bib87","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.jconrel.2009.11.008","article-title":"Biodegradable calcium phosphate nanoparticle with lipid coating for systemic siRNA delivery","volume":"142","author":"Li","year":"2010","journal-title":"J Control Release"},{"key":"10.1016\/j.apsb.2023.10.012_bib88","doi-asserted-by":"crossref","first-page":"4787","DOI":"10.1021\/acsnano.8b01516","article-title":"On the formation and morphology of lipid nanoparticles containing ionizable cationic lipids and siRNA","volume":"12","author":"Kulkarni","year":"2018","journal-title":"ACS Nano"},{"key":"10.1016\/j.apsb.2023.10.012_bib89","doi-asserted-by":"crossref","first-page":"18440","DOI":"10.1021\/jp303267y","article-title":"Lipid nanoparticles containing siRNA synthesized by microfluidic mixing exhibit an Electron-Dense nanostructured core","volume":"116","author":"Leung","year":"2012","journal-title":"J Phys Chem C Nanomater Interfaces"},{"key":"10.1016\/j.apsb.2023.10.012_bib90","doi-asserted-by":"crossref","first-page":"16982","DOI":"10.1021\/acsnano.1c04996","article-title":"Lipid nanoparticles\u2014from liposomes to mRNA vaccine delivery, a landscape of research diversity and advancement","volume":"15","author":"Tenchov","year":"2021","journal-title":"ACS Nano"},{"key":"10.1016\/j.apsb.2023.10.012_bib91","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1529\/biophysj.103.033480","article-title":"Nanostructure of cationic lipid-oligonucleotide complexes","volume":"87","author":"Weisman","year":"2004","journal-title":"Biophys J"},{"key":"10.1016\/j.apsb.2023.10.012_bib92","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1038\/nnano.2012.73","article-title":"Molecularly self-assembled nucleic acid nanoparticles for targeted in\u00a0vivo siRNA delivery","volume":"7","author":"Lee","year":"2012","journal-title":"Nat Nanotechnol"},{"key":"10.1016\/j.apsb.2023.10.012_bib93","doi-asserted-by":"crossref","first-page":"105","DOI":"10.2217\/nnm.13.192","article-title":"Lipid-based nanoparticles in the systemic delivery of siRNA","volume":"9","author":"Lin","year":"2014","journal-title":"Nanomedicine"},{"key":"10.1016\/j.apsb.2023.10.012_bib94","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1016\/S0140-6736(10)60357-1","article-title":"Postexposure protection of non-human primates against a lethal Ebola virus challenge with RNA interference: a proof-of-concept study","volume":"375","author":"Geisbert","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.apsb.2023.10.012_bib95","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1038\/nbt1122","article-title":"Potent and persistent in\u00a0vivo anti-HBV activity of chemically modified siRNAs","volume":"23","author":"Morrissey","year":"2005","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.apsb.2023.10.012_bib96","doi-asserted-by":"crossref","DOI":"10.1002\/adhm.202101202","article-title":"Functional sirna delivery by extracellular vesicle-liposome hybrid nanoparticles","volume":"11","author":"Evers","year":"2022","journal-title":"Adv Healthcare Mater"},{"key":"10.1016\/j.apsb.2023.10.012_bib97","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.jconrel.2011.10.009","article-title":"Liposome based systems for systemic siRNA delivery: stability in blood sets the requirements for optimal carrier design","volume":"158","author":"Buyens","year":"2012","journal-title":"J Control Release"},{"key":"10.1016\/j.apsb.2023.10.012_bib98","doi-asserted-by":"crossref","first-page":"4306","DOI":"10.1016\/j.biomaterials.2011.02.045","article-title":"Systemic delivery of siRNA to tumors using a lipid nanoparticle containing a tumor-specific cleavable PEG-lipid","volume":"32","author":"Hatakeyama","year":"2011","journal-title":"Biomaterials"},{"key":"10.1016\/j.apsb.2023.10.012_bib99","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.jconrel.2011.10.020","article-title":"Calcium phosphate nanoparticles with an asymmetric lipid bilayer coating for sirna delivery to the tumor","volume":"158","author":"Li","year":"2012","journal-title":"J Control Release"},{"key":"10.1016\/j.apsb.2023.10.012_bib100","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.chemphyslip.2005.02.003","article-title":"Effect of grafted PEG on liposome size and on compressibility and packing of lipid bilayer","volume":"135","author":"Garbuzenko","year":"2005","journal-title":"Chem Phys Lipids"},{"key":"10.1016\/j.apsb.2023.10.012_bib101","first-page":"1178","article-title":"Effect of polyethylene glycol-lipid derivatives on the stability of grafted liposomes","volume":"46","author":"Xu","year":"2011","journal-title":"Yao Xue Xue Bao"},{"key":"10.1016\/j.apsb.2023.10.012_bib102","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.ijpharm.2005.10.010","article-title":"Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles","volume":"307","author":"Owensiii","year":"2006","journal-title":"Int J Pharm"},{"key":"10.1016\/j.apsb.2023.10.012_bib103","doi-asserted-by":"crossref","first-page":"17646","DOI":"10.1021\/acsami.8b03469","article-title":"pH-Controlled liposomes for enhanced cell penetration in tumor environment","volume":"10","author":"Barattin","year":"2018","journal-title":"ACS Appl Mater Interfaces"},{"key":"10.1016\/j.apsb.2023.10.012_bib104","doi-asserted-by":"crossref","first-page":"3164","DOI":"10.7150\/thno.22164","article-title":"Pre-existing anti-polyethylene glycol antibody reduces the therapeutic efficacy and pharmacokinetics of PEGylated liposomes","volume":"8","author":"Hsieh","year":"2018","journal-title":"Theranostics"},{"key":"10.1016\/j.apsb.2023.10.012_bib105","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.jconrel.2013.07.026","article-title":"The accelerated blood clearance (ABC) phenomenon: clinical challenge and approaches to manage","volume":"172","author":"Abu Lila","year":"2013","journal-title":"J Control Release"},{"key":"10.1016\/j.apsb.2023.10.012_bib106","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/S0022-3565(24)29419-2","article-title":"Factors affecting the accelerated blood clearance of polyethylene glycol-liposomes upon repeated injection","volume":"298","author":"Laverman","year":"2001","journal-title":"J Pharmacol Exp Therapeut"},{"key":"10.1016\/j.apsb.2023.10.012_bib107","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1021\/nn800669n","article-title":"Shedding light on tumors using nanoparticles","volume":"2","author":"Rao","year":"2008","journal-title":"ACS Nano"},{"key":"10.1016\/j.apsb.2023.10.012_bib108","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/0005-2736(94)90231-3","article-title":"Liposome-complement interactions in rat serum: implications for liposome survival studies","volume":"1191","author":"Devine","year":"1994","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.apsb.2023.10.012_bib109","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1023\/A:1018965121222","article-title":"Enhanced hepatic uptake of liposomes through complement activation depending on the size of liposomes","volume":"11","author":"Harashima","year":"1994","journal-title":"Pharm Res (N Y)"},{"key":"10.1016\/j.apsb.2023.10.012_bib110","doi-asserted-by":"crossref","first-page":"2298","DOI":"10.2174\/138161210791920496","article-title":"Factors that control the circulation time of nanoparticles in blood: challenges, solutions and future prospects","volume":"16","author":"Yoo","year":"2010","journal-title":"Curr Pharmaceut Des"},{"key":"10.1016\/j.apsb.2023.10.012_bib111","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.jconrel.2011.09.098","article-title":"The journey of a drug-carrier in the body: an anatomo-physiological perspective","volume":"161","author":"Bertrand","year":"2012","journal-title":"J Control Release"},{"key":"10.1016\/j.apsb.2023.10.012_bib112","doi-asserted-by":"crossref","first-page":"3883","DOI":"10.1021\/acs.chemrev.5b00578","article-title":"Chemical components for the design of temperature-responsive vesicles as cancer therapeutics","volume":"116","author":"Al-Ahmady","year":"2016","journal-title":"Chem Rev"},{"key":"10.1016\/j.apsb.2023.10.012_bib113","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/S0006-3495(90)82444-9","article-title":"Elastic deformation and failure of lipid bilayer membranes containing cholesterol","volume":"58","author":"Needham","year":"1990","journal-title":"Biophys J"},{"key":"10.1016\/j.apsb.2023.10.012_bib114","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1038\/bjc.1995.430","article-title":"Sphingomyelin-cholesterol liposomes significantly enhance the pharmacokinetic and therapeutic properties of vincristine in murine and human tumour models","volume":"72","author":"Webb","year":"1995","journal-title":"Br J Cancer"},{"key":"10.1016\/j.apsb.2023.10.012_bib115","doi-asserted-by":"crossref","first-page":"4264","DOI":"10.1021\/acs.nanolett.0c00752","article-title":"A nanoprimer to improve the systemic delivery of siRNA and mRNA","volume":"20","author":"Saunders","year":"2020","journal-title":"Nano Lett"},{"key":"10.1016\/j.apsb.2023.10.012_bib116","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.tibtech.2013.09.007","article-title":"Ligand-targeted liposome design: challenges and fundamental considerations","volume":"32","author":"Noble","year":"2014","journal-title":"Trends Biotechnol"},{"key":"10.1016\/j.apsb.2023.10.012_bib117","first-page":"d717","article-title":"Targeting hepatocytes for drug and gene delivery: emerging novel approaches and applications","volume":"7","author":"Wu","year":"2002","journal-title":"Front Biosci"},{"key":"10.1016\/j.apsb.2023.10.012_bib118","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1023\/A:1007501122611","article-title":"In\u00a0vivo gene delivery to the liver using novel galactosylated cationic liposomes","volume":"17","author":"Kawakami","year":"2000","journal-title":"Pharm Res (N Y)"},{"key":"10.1016\/j.apsb.2023.10.012_bib119","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1248\/bpb.34.1338","article-title":"Galactose-modified cationic liposomes as a liver-targeting delivery system for small interfering RNA","volume":"34","author":"Sonoke","year":"2011","journal-title":"Biol Pharm Bull"},{"key":"10.1016\/j.apsb.2023.10.012_bib120","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1208\/s12248-012-9330-0","article-title":"Challenges in development of targeted liposomal therapeutics","volume":"14","author":"Sawant","year":"2012","journal-title":"AAPS J"},{"key":"10.1016\/j.apsb.2023.10.012_bib121","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0169-409X(97)00083-5","article-title":"Ligand-targeted liposomes","volume":"29","author":"Willis","year":"1998","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.apsb.2023.10.012_bib122","doi-asserted-by":"crossref","first-page":"3747","DOI":"10.1002\/adma.201200454","article-title":"Peptides as targeting elements and tissue penetration devices for nanoparticles","volume":"24","author":"Ruoslahti","year":"2012","journal-title":"Adv Mater"},{"key":"10.1016\/j.apsb.2023.10.012_bib123","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1080\/1061186X.2021.1973481","article-title":"Cationic liposome decorated with cyclic RGD peptide for targeted delivery of anti-STAT3 siRNA to melanoma cancer cells","volume":"30","author":"Khabazian","year":"2022","journal-title":"J Drug Target"},{"key":"10.1016\/j.apsb.2023.10.012_bib124","doi-asserted-by":"crossref","first-page":"5226","DOI":"10.1016\/j.biomaterials.2014.03.017","article-title":"Tumor-targeting dual peptides-modified cationic liposomes for delivery of siRNA and docetaxel to gliomas","volume":"35","author":"Yang","year":"2014","journal-title":"Biomaterials"},{"key":"10.1016\/j.apsb.2023.10.012_bib125","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1038\/bjc.1996.625","article-title":"Targeting of stealth liposomes to erbB-2 (Her\/2) receptor: in\u00a0vitro and in\u00a0vivo studies","volume":"74","author":"Goren","year":"1996","journal-title":"Br J Cancer"},{"key":"10.1016\/j.apsb.2023.10.012_bib126","first-page":"6551","article-title":"In\u00a0vivo fate of folate-targeted polyethylene-glycol liposomes in tumor-bearing mice","volume":"9","author":"Gabizon","year":"2003","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.apsb.2023.10.012_bib127","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.addr.2017.07.021","article-title":"Nonviral cancer gene therapy: delivery cascade and vector nanoproperty integration","volume":"115","author":"Zhou","year":"2017","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.apsb.2023.10.012_bib128","article-title":"'Adhesion and release' nanoparticle-mediated efficient inhibition of platelet activation disrupts endothelial barriers for enhanced drug delivery in tumors","volume":"269","author":"Cao","year":"2020","journal-title":"Biomaterials"},{"key":"10.1016\/j.apsb.2023.10.012_bib129","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1038\/s41467-018-04390-7","article-title":"Immunogene therapy with fusogenic nanoparticles modulates macrophage response to Staphylococcus aureus","volume":"9","author":"Kim","year":"2018","journal-title":"Nat Commun"},{"key":"10.1016\/j.apsb.2023.10.012_bib130","doi-asserted-by":"crossref","DOI":"10.1002\/adma.201902952","article-title":"Securing the payload, finding the cell, and avoiding the endosome: peptide-targeted, fusogenic porous silicon nanoparticles for delivery of siRNA","volume":"31","author":"Kim","year":"2019","journal-title":"Adv Mater"},{"key":"10.1016\/j.apsb.2023.10.012_bib131","doi-asserted-by":"crossref","first-page":"20","DOI":"10.7150\/thno.76894","article-title":"Engineered biomembrane-derived nanoparticles for nanoscale theranostics","volume":"13","author":"Wu","year":"2023","journal-title":"Theranostics"},{"key":"10.1016\/j.apsb.2023.10.012_bib132","doi-asserted-by":"crossref","first-page":"10049","DOI":"10.1021\/acsnano.6b04695","article-title":"Cancer cell membrane-biomimetic nanoparticles for homologous-targeting dual-modal imaging and photothermal therapy","volume":"10","author":"Chen","year":"2016","journal-title":"ACS Nano"},{"key":"10.1016\/j.apsb.2023.10.012_bib133","article-title":"Cell membrane\u2013camouflaged liposomes for tumor cell\u2013selective glycans engineering and imaging in\u00a0vivo","volume":"118","author":"Liu","year":"2021","journal-title":"Proc Natl Acad Sci U\u00a0S\u00a0A"},{"key":"10.1016\/j.apsb.2023.10.012_bib134","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1038\/nbt.2614","article-title":"Efficiency of siRNA delivery by lipid nanoparticles is limited by endocytic recycling","volume":"31","author":"Sahay","year":"2013","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.apsb.2023.10.012_bib135","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1038\/nbt.2612","article-title":"Image-based analysis of lipid nanoparticle-mediated siRNA delivery, intracellular trafficking and endosomal escape","volume":"31","author":"Gilleron","year":"2013","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.apsb.2023.10.012_bib136","doi-asserted-by":"crossref","first-page":"E3351","DOI":"10.1073\/pnas.1720542115","article-title":"Successful reprogramming of cellular protein production through mRNA delivered by functionalized lipid nanoparticles","volume":"115","author":"Yanez Arteta","year":"2018","journal-title":"Proc Natl Acad Sci U\u00a0S\u00a0A"},{"key":"10.1016\/j.apsb.2023.10.012_bib137","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.jconrel.2006.06.024","article-title":"Cationic lipids, lipoplexes and intracellular delivery of genes","volume":"116","author":"Wasungu","year":"2006","journal-title":"J Control Release"},{"key":"10.1016\/j.apsb.2023.10.012_bib138","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1042\/BST0350068","article-title":"Gene delivery by cationic lipids: in and out of an endosome","volume":"35","author":"Hoekstra","year":"2007","journal-title":"Biochem Soc Trans"},{"key":"10.1016\/j.apsb.2023.10.012_bib139","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.nantod.2014.04.011","article-title":"Intracellular delivery of nanomaterials: how to catch endosomal escape in the act","volume":"9","author":"Martens","year":"2014","journal-title":"Nano Today"},{"key":"10.1016\/j.apsb.2023.10.012_bib140","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1093\/nar\/gkv008","article-title":"A KALA-modified lipid nanoparticle containing CpG-free plasmid DNA as a potential DNA vaccine carrier for antigen presentation and as an immune-stimulative adjuvant","volume":"43","author":"Miura","year":"2015","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.apsb.2023.10.012_bib141","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1007\/s11705-014-1457-3","article-title":"Design of nanocarriers for efficient cellular uptake and endosomal release of small molecule and nucleic acid drugs: learning from virus","volume":"8","author":"Mundra","year":"2014","journal-title":"Front Chem Sci Eng"},{"key":"10.1016\/j.apsb.2023.10.012_bib142","doi-asserted-by":"crossref","first-page":"28256","DOI":"10.1039\/D0CP05111J","article-title":"DOPC versus DOPE as a helper lipid for gene-therapies: molecular dynamics simulations with DLin-MC3-DMA","volume":"22","author":"Ermilova","year":"2020","journal-title":"Phys Chem Chem Phys"},{"key":"10.1016\/j.apsb.2023.10.012_bib143","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1002\/jcph.1553","article-title":"Pharmacokinetics of patisiran, the first approved RNA interference therapy in patients with hereditary transthyretin-Mediated amyloidosis","volume":"60","author":"Zhang","year":"2020","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.apsb.2023.10.012_bib144","doi-asserted-by":"crossref","DOI":"10.1016\/j.dmpk.2021.100424","article-title":"Difference in the lipid nanoparticle technology employed in three approved siRNA (Patisiran) and mRNA (COVID-19 vaccine) drugs","volume":"41","author":"Suzuki","year":"2021","journal-title":"Drug Metabol Pharmacokinet"},{"key":"10.1016\/j.apsb.2023.10.012_bib145","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.jconrel.2006.04.014","article-title":"Toxicity of cationic lipids and cationic polymers in gene delivery","volume":"114","author":"Lv","year":"2006","journal-title":"J Control Release"},{"key":"10.1016\/j.apsb.2023.10.012_bib146","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/nbt.1733","article-title":"Expression of therapeutic proteins after delivery of chemically modified mRNA in mice","volume":"29","author":"Kormann","year":"2011","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.apsb.2023.10.012_bib147","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1038\/nbt1161","article-title":"Activation of the mammalian immune system by siRNAs","volume":"23","author":"Marques","year":"2005","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.apsb.2023.10.012_bib148","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/nbt1081","article-title":"Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA","volume":"23","author":"Judge","year":"2005","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.apsb.2023.10.012_bib149","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1126\/science.1068883","article-title":"Decoding the patterns of self and nonself by the innate immune system","volume":"296","author":"Medzhitov","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.apsb.2023.10.012_bib150","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1093\/intimm\/dxt040","article-title":"Chemical modifications on siRNAs avoid Toll-like-receptor-mediated activation of the hepatic immune system in\u00a0vivo and in\u00a0vitro","volume":"26","author":"Broering","year":"2014","journal-title":"Int Immunol"},{"key":"10.1016\/j.apsb.2023.10.012_bib151","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.jconrel.2015.08.051","article-title":"N1-methylpseudouridine-incorporated mRNA outperforms pseudouridine-incorporated mRNA by providing enhanced protein expression and reduced immunogenicity in mammalian cell lines and mice","volume":"217","author":"Andries","year":"2015","journal-title":"J Control Release"},{"key":"10.1016\/j.apsb.2023.10.012_bib152","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1038\/mt.2009.208","article-title":"Evaluation of efficacy, biodistribution, and inflammation for a potent siRNA nanoparticle: effect of dexamethasone co-treatment","volume":"18","author":"Abrams","year":"2010","journal-title":"Mol Ther"},{"key":"10.1016\/j.apsb.2023.10.012_bib153","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1177\/0300985817738095","article-title":"Safety evaluation of lipid nanoparticle-formulated modified mRNA in the Sprague\u2012Dawley rat and cynomolgus monkey","volume":"55","author":"Sedic","year":"2018","journal-title":"Vet Pathol"},{"key":"10.1016\/j.apsb.2023.10.012_bib154","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.molimm.2014.06.038","article-title":"Complement activation-related pseudoallergy: a stress reaction in blood triggered by nanomedicines and biologicals","volume":"61","author":"Szebeni","year":"2014","journal-title":"Mol Immunol"},{"key":"10.1016\/j.apsb.2023.10.012_bib155","doi-asserted-by":"crossref","DOI":"10.1038\/mtna.2014.61","article-title":"Shielding of lipid nanoparticles for siRNA delivery: impact on physicochemical properties, cytokine induction, and efficacy","volume":"3","author":"Kumar","year":"2014","journal-title":"Mol Ther Nucleic Acids"},{"key":"10.1016\/j.apsb.2023.10.012_bib156","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s40425-018-0371-5","article-title":"Dexamethasone-induced immunosuppression: mechanisms and implications for immunotherapy","volume":"6","author":"Giles","year":"2018","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.apsb.2023.10.012_bib157","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1056\/NEJMoa1208760","article-title":"Safety and efficacy of RNAi therapy for transthyretin amyloidosis","volume":"369","author":"Coelho","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.apsb.2023.10.012_bib158","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s12964-017-0177-y","article-title":"The role of JAK-STAT signaling pathway and its regulators in the fate of T helper cells","volume":"15","author":"Seif","year":"2017","journal-title":"Cell Commun Signal"},{"key":"10.1016\/j.apsb.2023.10.012_bib159","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1038\/mt.2010.282","article-title":"Mechanistically probing lipid-siRNA nanoparticle-associated toxicities identifies Jak inhibitors effective in mitigating multifaceted toxic responses","volume":"19","author":"Tao","year":"2011","journal-title":"Mol Ther"},{"key":"10.1016\/j.apsb.2023.10.012_bib160","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1146\/annurev.bi.50.070181.002245","article-title":"The proteolytic activation systems of complement","volume":"50","author":"Reid","year":"1981","journal-title":"Annu Rev Biochem"},{"key":"10.1016\/j.apsb.2023.10.012_bib161","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.ymthe.2005.09.014","article-title":"Hypersensitivity and loss of disease site targeting caused by antibody responses to PEGylated liposomes","volume":"13","author":"Judge","year":"2006","journal-title":"Mol Ther"},{"key":"10.1016\/j.apsb.2023.10.012_bib162","doi-asserted-by":"crossref","first-page":"3654","DOI":"10.1073\/pnas.0809959106","article-title":"Effect of cholesterol on the structure of a phospholipid bilayer","volume":"106","author":"De Meyer","year":"2009","journal-title":"Proc Natl Acad Sci U\u00a0S\u00a0A"},{"key":"10.1016\/j.apsb.2023.10.012_bib163","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/0005-2736(89)90307-6","article-title":"Serum opsonins and phagocytosis of saturated and unsaturated phospholipid liposomes","volume":"984","author":"Moghimi","year":"1989","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.apsb.2023.10.012_bib164","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1038\/nature18300","article-title":"Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy","volume":"534","author":"Kranz","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.apsb.2023.10.012_bib165","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/s41565-020-0669-6","article-title":"Selective organ targeting (SORT) nanoparticles for tissue-specific mRNA delivery and CRISPR-Cas gene editing","volume":"15","author":"Cheng","year":"2020","journal-title":"Nat Nanotechnol"},{"key":"10.1016\/j.apsb.2023.10.012_bib166","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.jconrel.2018.10.015","article-title":"PECAM-1 directed re-targeting of exogenous mRNA providing two orders of magnitude enhancement of vascular delivery and expression in lungs independent of apolipoprotein E-mediated uptake","volume":"291","author":"Parhiz","year":"2018","journal-title":"J Control Release"},{"key":"10.1016\/j.apsb.2023.10.012_bib167","doi-asserted-by":"crossref","first-page":"e96","DOI":"10.1038\/mtna.2013.22","article-title":"Efficient biodistribution and gene silencing in the lung epithelium via intravenous liposomal delivery of siRNA","volume":"2","author":"Mccaskill","year":"2013","journal-title":"Mol Ther Nucleic Acids"},{"key":"10.1016\/j.apsb.2023.10.012_bib168","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1038\/s41563-020-00886-0","article-title":"Membrane-destabilizing ionizable phospholipids for organ-selective mRNA delivery and CRISPR-Cas gene editing","volume":"20","author":"Liu","year":"2021","journal-title":"Nat Mater"},{"key":"10.1016\/j.apsb.2023.10.012_bib169","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/s41586-020-2537-9","article-title":"An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma","volume":"585","author":"Sahin","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.apsb.2023.10.012_bib170","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s13346-018-0583-8","article-title":"Influence of PEG coating on the biodistribution and tumor accumulation of pH-sensitive liposomes","volume":"9","author":"Nunes","year":"2019","journal-title":"Drug Deliv Transl Res"},{"key":"10.1016\/j.apsb.2023.10.012_bib171","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1038\/mt.2013.57","article-title":"Gene silencing via RNAi and siRNA quantification in tumor tissue using MEND, a liposomal siRNA delivery system","volume":"21","author":"Sakurai","year":"2013","journal-title":"Mol Ther"},{"key":"10.1016\/j.apsb.2023.10.012_bib172","doi-asserted-by":"crossref","first-page":"3858","DOI":"10.3390\/ijms19123859","article-title":"A promising biocompatible platform: lipid-based and bio-inspired smart drug delivery systems for cancer therapy","volume":"19","author":"Kim","year":"2018","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.apsb.2023.10.012_bib173","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.aaz6108","article-title":"Targeted gene silencing in\u00a0vivo by platelet membrane-coated metal-organic framework nanoparticles","volume":"6","author":"Zhuang","year":"2020","journal-title":"Sci Adv"},{"key":"10.1016\/j.apsb.2023.10.012_bib174","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1038\/s41587-023-01679-x","article-title":"Combinatorial design of nanoparticles for pulmonary mRNA delivery and genome editing","volume":"41","author":"Li","year":"2023","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.apsb.2023.10.012_bib175","doi-asserted-by":"crossref","first-page":"7300","DOI":"10.1021\/acs.nanolett.5b02497","article-title":"Optimization of lipid nanoparticle formulations for mRNA delivery in\u00a0vivo with fractional factorial and definitive screening designs","volume":"15","author":"Kauffman","year":"2015","journal-title":"Nano Lett"},{"key":"10.1016\/j.apsb.2023.10.012_bib176","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ymeth.2015.02.019","article-title":"Methods of isolating extracellular vesicles impact down-stream analyses of their cargoes","volume":"87","author":"Taylor","year":"2015","journal-title":"Methods"}],"container-title":["Acta Pharmaceutica Sinica B"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211383523004069?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211383523004069?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T17:06:15Z","timestamp":1761930375000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211383523004069"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":176,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["S2211383523004069"],"URL":"https:\/\/doi.org\/10.1016\/j.apsb.2023.10.012","relation":{},"ISSN":["2211-3835"],"issn-type":[{"value":"2211-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lipid nanovehicles overcome barriers to systemic RNA delivery: Lipid components, fabrication methods, and rational design","name":"articletitle","label":"Article Title"},{"value":"Acta Pharmaceutica Sinica B","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.apsb.2023.10.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V. on behalf of Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences.","name":"copyright","label":"Copyright"}]}}